EUCTR2005-003999-38-DE进行中（未招募）不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects 18 years of age and older.
- •Subjects requiring elective spinal fusion surgery involving 3 to 7 vertebral levels with instrumentation.
- •Documented, signed, dated informed consent obtained prior to any study specific procedures being performed. Procedures performed within 30 days of screening (including safety labs, electrocardiogram [ECG], chest x-ray, and physical exam) will be allowed to qualify a patient for study entry once the informed consent has been signed. However, laboratory results and ECG analyses used to qualify a patient need to be performed by the central laboratory.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects with previous exposure to aprotinin in the last 6 months. If the subject has undergone cardiac surgery in the last 6 months, all attempts should be made to ascertain if aprotinin was administered during cardiac surgery. If no records are available, or if the subject received aprotinin, the subject should be excluded.
- •Subjects with a known or suspected allergy to aprotinin.
- •Subjects with sepsis or a known bone infection.
- •Subjects with known bone malignancy.
- •Subjects with a creatinine clearance less than 30 mL/min as calculated by the Cockcroft-Gault formula.
- •Subjects with a history of bleeding diathesis or known coagulation factor deficiency.
- •Subjects with failure of a major organ system or any active significant medical illness that in the opinion of the Investigator is likely to affect the subject’s ability to complete the study or precludes the subject’s participation in the study.
- •Subjects who refuse to receive allogenic blood products for religious or other reasons.
- •Subjects whose preoperative red blood cell volume is so low that a blood transfusion would be likely to be given perioperatively (preoperative hematocrit or hemoglobin values <24% or <8 g/dl, respectively).
- •Subjects who have participated in an investigational drug study within the past 30 days.
- •Subjects with a history of deep vein thrombosis or pulmonary embolism.
- •Subjects who are pregnant or breast feeding.
- •Women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative pregnancy test at screening.
- •Women of childbearing potential who are not using a reliable method of contraception. Methods of contraception that are considered reliabel are intrauterine devices (IUDs), birth control pills, hormonal implants/patches, and barrier contraception which is used with spermicidal products. The Rhythm method is not considered a reliable method of contraception.
- •Planned use of other antifibrinolytic agents
- •Subjects on chronic anticoagulant treatment with Vit K antagonists that cannot be temporarily discontinued for the surgical procedure (as per local practices).
研究者
相似试验
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative ColitisEUCTR2014-004559-29-Outside-EU/EEAAbbVie Inc.274
进行中（未招募）
1 期
Efficacy and safety of QGE031 versus placebo in patients aged 18-75 years with asthma not adequately controlled with standard of care medication (inhaled corticosteroids plus long lasting beta agonists with or without oral corticosteroids)Severe AsthmaMedDRA version: 18.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-003155-57-GBovartis Pharma Services AG10
进行中（未招募）
1 期
Efficacy and Safety of BMS-986165 versus Placebo and Active Comparator in Subjects with PsoriasisModerate-to-Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2018-001926-25-PLBristol-Myers Squibb International Corporation600
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyComparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subjects with Type 2 Diabetes - Post-PrandialEUCTR2007-000486-38-NLTakeda Global Research & Development Centre (Europe) Ltd.,71
进行中（未招募）
1 期
Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patientsCharcot Marie Tooth Type 1AMedDRA version: 20.0Level: LLTClassification code 10008414Term: Charcot-Marie-Tooth diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004805-30-DKPharnext SCA387